Literature DB >> 266538

Multiple skin testing of tuberculosis patients with a range of new tuberculins, and a comparison with leprosy and Mycobacterium ulcerans infection.

M J Shield, J L Stanford, R C Paul, J W Carswell.   

Abstract

Four hundred and seventy tuberculosis patients were each skin tested with four of a range of 17 mycobacterial reagents in four countries in all of which tuberculosis and leprosy were endemic. Sixteen of the reagents were new tuberculins prepared from extracts of living mycobacteria disrupted by ultrasonic disintegration and the last was PPD, RT23.The effect that tuberculosis exerted on the delayed-type skin test response to these antigens was assessed by comparing results for tuberculosis patients with those for Tuberculin positive and Tuberculin negative control populations. Tuberculosis patients on Rifampicin therapy showed no difference in their skin test responses to any of the antigens from those patients on other forms of antituberculosis treatment.Amongst the normal population it was found that possession of Tuberculin positivity was associated with an enhanced response to all the other mycobacterial antigens with the exception of A(*)-in which demonstrated a reciprocal relationship with Tuberculin in Burma. It was also noted, in Burma particularly, that sensitization to mycobacterial species other than Mycobacterium tuberculosis, especially to the slow growers, plays a role in determining responses to different mycobacterial species.In tuberculosis patients enhanced skin test responses were also seen but only in those countries, e.g. Libya, where the prevalence of mycobacterial species was low. Where mycobacteria were common, as in Burma, the converse was true and tuberculosis was associated with a diminished skin test response to each antigen. The high prevalence of A(*)-in positivity in Burma, its reciprocal relationship with Tuberculin there and the results for all the antigens in the tuberculosis patients indicate that the cell mediated skin test response may have a threshold. If this is exceeded the skin test becomes negative so that non-reactors then include those who have been excessively sensitized as well as those who have not been sensitized. Despite this, a greater percentage of tuberculosis patients in each country responded to the specific reagent Tuberculin than did the control populations and their mean positive induration sizes were consistently larger. Nevertheless, amongst the tuberculosis patients in Burma 13% were complete non-reactors to Tuberculin and this apparent anergy also applied to the other reagents with which these individuals were tested.This differs from lepromatous leprosy where the anergic state pertains exclusively to M. leprae and a few seemingly closely related species. The breadth of anergy in M. ulcerans infection has not been measured but it is known to effect both Burulin and the PPD, RT23.Just as in leprosy and M. ulcerans infection, tuberculosis can be shown to have a disease spectrum here detected by multiple skin testing. The significance of this spectrum and its similarities with and differences from that of the other mycobacterioses is discussed.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 266538      PMCID: PMC2129877          DOI: 10.1017/s0022172400056230

Source DB:  PubMed          Journal:  J Hyg (Lond)        ISSN: 0022-1724


  9 in total

1.  Multiple skin testing of Kenyan schoolchildren with a series of new tuberculins.

Authors:  R C Paul; J L Stanford; O Misljenóvic; J Lefering
Journal:  J Hyg (Lond)       Date:  1975-10

2.  Editorials: Tuberculins and other mycobacterins.

Authors:  E H Runyon
Journal:  Am Rev Respir Dis       Date:  1976-06

3.  Taxonomic studies on the leprosy bacillus.

Authors:  J L Stanford; G A Rook
Journal:  Int J Lepr Other Mycobact Dis       Date:  1976 Jan-Jun

4.  Is the macrophage the site of the immunosuppressive action of rifampicin?

Authors:  G A Rook
Journal:  Tubercle       Date:  1973-12

5.  A preliminary report on some studies of environmental mycobacteria.

Authors:  J L Stanford; R C Paul
Journal:  Ann Soc Belg Med Trop       Date:  1973

6.  In vivo and in vitro suppression of humoral and cellular immunological response by rifampicin.

Authors:  E Păunescu
Journal:  Nature       Date:  1970-12-19       Impact factor: 49.962

7.  Multiple skin testing in leprosy.

Authors:  R C Paul; J L Stanford; J W Carswell
Journal:  J Hyg (Lond)       Date:  1975-08

8.  The effect of desert conditions on the reactivity of Libyan schoolchildren to a range of new tuberculins.

Authors:  J L Stanford; M J Shield; R C Paul; A Khalil; R S Tobgi; A Wallace
Journal:  J Hyg (Lond)       Date:  1976-08

9.  The production and preliminary investigation of Burulin, a new skin test reagent for Mycobacterium ulcerans infection.

Authors:  J L Stanford; W D Revill; W J Gunthorpe; J M Grange
Journal:  J Hyg (Lond)       Date:  1975-02
  9 in total
  13 in total

1.  Measurements of blood flow and histometry of the cellular infiltrate in tuberculin skin test responses of the typical Koch type and the non-turgid variant form (Listeria-type) in pulmonary tuberculosis patients and apparently healthy controls.

Authors:  R C Potts; J S Beck; J H Gibbs; J M Grange; T Kardjito; J L Stanford
Journal:  Int J Exp Pathol       Date:  1992-10       Impact factor: 1.925

2.  HLA-DR and tuberculin tests in rheumatoid arthritis and tuberculosis.

Authors:  G M Bahr; M A Sattar; J L Stanford; M A Shaaban; B Al Shimali; Z Siddiqui; M Gabriel; M Al Saffar; A Shahin; T D Chugh
Journal:  Ann Rheum Dis       Date:  1989-01       Impact factor: 19.103

3.  The method of preparation of an antigen may influence the cellular reaction to it in skin tests for delayed hypersensitivity: comparison between responses to two different reagents prepared from Mycobacterium tuberculosis.

Authors:  S M Morley; J S Beck; J M Grange; R A Brown; T Kardjito
Journal:  Clin Exp Immunol       Date:  1987-09       Impact factor: 4.330

4.  Skin test responsiveness to four new tuberculins in patients with chronic obstructive airways disease receiving short term high doses of, or long term maintenance treatment with, prednisolone: clinical appearances and histometric studies.

Authors:  J G Lowe; J S Beck; J H Gibbs; R A Brown; R C Potts; J M Grange; J L Stanford
Journal:  J Clin Pathol       Date:  1987-01       Impact factor: 3.411

5.  Antibody levels to mycobacteria in relation to HLA type: evidence for non-HLA-linked high levels of antibody to the 65 kD heat shock protein of M. bovis in rheumatoid arthritis.

Authors:  G M Bahr; G A Rook; M al-Saffar; J Van Embden; J L Stanford; K Behbehani
Journal:  Clin Exp Immunol       Date:  1988-11       Impact factor: 4.330

6.  HLA-DR-associated isotype-specific regulation of antibody levels to mycobacteria in rheumatoid arthritis.

Authors:  G M Bahr; G A Rook; A Shahin; J L Stanford; M I Sattar; K Behbehani
Journal:  Clin Exp Immunol       Date:  1988-04       Impact factor: 4.330

7.  The cellular responses of tuberculosis and leprosy patients and of healthy controls in skin tests to 'new tuberculin' and leprosin A.

Authors:  J S Beck; S M Morley; J H Gibbs; R C Potts; M I Ilias; T Kardjito; J M Grange; J Stanford; R A Brown
Journal:  Clin Exp Immunol       Date:  1986-06       Impact factor: 4.330

8.  Serologic response to culture filtrate antigens of Mycobacterium ulcerans during Buruli ulcer disease.

Authors:  K M Dobos; E A Spotts; B J Marston; C R Horsburgh; C H King
Journal:  Emerg Infect Dis       Date:  2000 Mar-Apr       Impact factor: 6.883

9.  Raised serum IgG and IgA antibodies to mycobacterial antigens in rheumatoid arthritis.

Authors:  G Tsoulfa; G A Rook; J D Van-Embden; D B Young; A Mehlert; D A Isenberg; F C Hay; P M Lydyard
Journal:  Ann Rheum Dis       Date:  1989-02       Impact factor: 19.103

10.  Unresponsiveness to skin testing with bacterial antigens in patients with haemophilia A not apparently infected with human immunodeficiency virus (HIV).

Authors:  R A Sharp; S M Morley; J S Beck; G E Urquhart
Journal:  J Clin Pathol       Date:  1987-08       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.